Granted Patent
B2
US 12,186,282 · App. 17/957,932 · Granted Jan 7, 2025
Treatment of 22Q11.2 deletion syndrome with cannabidiol
Assignee:
HARMONY BIOSCIENCES MANAGEMENT, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q 11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q 11.2 deletion syndrome are treated in the subject.
Claims (21)
1. A method of treating one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome in a subject, the method comprising:
administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject.
2. The method of claim 1 , wherein the administration of CBD is effective for the treatment of general anxiety in the subject.
3. The method of claim 1 , wherein the CBD is (−)-CBD.
4. The method of claim 1 , wherein the effective amount of CBD is between about 50 mg and about 1000 mg total daily.
5. The method of claim 1 , wherein the CBD is formulated as a gel.
6. The method of claim 1 , wherein the CBD is administered in a single daily dose.
7. The method of claim 1 , wherein the CBD is administered in two daily doses.
8. The method of claim 1 , wherein the CBD is formulated as a permeation-enhanced gel.
9. The method of claim 1 , wherein the CBD is transdermally administered on the subject's arm.
10. The method of claim 1 , wherein the CBD is a synthetic CBD.
11. The method of claim 1 , wherein the CBD is botanically derived.
12. The method of claim 1 , wherein the CBD is purified.
13. The method of claim 1 , wherein administering comprises transdermally administering.
14. The method of claim 13 , wherein transdermally administering an effective amount of cannabidiol (CBD) reduces an intensity of at least one adverse event relative to orally administering CBD.
15. The method of claim 14 , wherein the at least one adverse event is selected from the group consisting of somnolence, psychoactive effects, liver function, and GI related adverse events.
16. The method of claim 1 , wherein the effective amount of CBD is about 125 mg total daily.
17. The method of claim 1 , wherein the effective amount of CBD is about 250 mg total daily.
18. The method of claim 1 , wherein the effective amount of CBD is about 500 mg total daily.
19. The method of claim 1 , wherein the effective amount of CBD is about 750 mg total daily.
20. The method of claim 1 , wherein the effective amount of CBD is about 1000 mg total daily.
Assignments (3)
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS
Recorded May 18, 2026
From: HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.)
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075642/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 21, 2024
From: SEBREE, TERRI; GUTTERMAN, DONNA
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 069432/0223 →
CHANGE OF NAME
Recorded Nov 21, 2024
From: ZYNERBA PHARMACEUTICALS, INC.
To: HARMONY BIOSCIENCES MANAGEMENT, INC.
Reel/Frame 069432/0319 →
Continuity (4)
Provisional Application
62895279
· Sep 3, 2019
Provisional Application
62779591
· Dec 14, 2018
References Cited (136)
US 7423026B2
· Jarvinen et al.
· 2008
[cited by applicant]
US 8293786B2
· Stinchcomb et al.
· 2012
[cited by applicant]
US 8435556B2
· Stinchcomb et al.
· 2013
[cited by applicant]
US 8449908B2
· Stinchcomb et al.
· 2013
[cited by applicant]
US 9375417B2
· Smith et al.
· 2016
[cited by applicant]
US 9447019B2
· Mechoulam et al.
· 2016
[cited by applicant]
US 9533942B2
· Stinchcomb et al.
· 2017
[cited by applicant]
US 9675656B2
· Crowley
· 2017
[cited by applicant]
US 9730911B2
· Verzura et al.
· 2017
[cited by applicant]
US 9782360B2
· Mechoulam et al.
· 2017
[cited by applicant]
US 9943491B2
· De Vries et al.
· 2018
[cited by applicant]
US 20080139472A1
· Lauterborn et al.
· 2008
[cited by applicant]
US 20100273895A1
· Stinchcomb et al.
· 2010
[cited by applicant]
US 20110052694A1
· Stinchcomb et al.
· 2011
[cited by applicant]
US 20160000843A1
· Lowe et al.
· 2016
[cited by applicant]
US 20160022627A2
· Smith
· 2016
[cited by applicant]
US 20160256410A1
· Aung-Din
· 2016
[cited by applicant]
US 20160271252A1
· Vangara et al.
· 2016
[cited by applicant]
US 20160338974A1
· Aung-Din
· 2016
[cited by applicant]
US 20170348276A1
· Bryson et al.
· 2017
[cited by applicant]
US 20210196669A1
· Bar-Lev Schleider et al.
· 2021
[cited by applicant]
US 20210369643A1
· Sebree et al.
· 2021
[cited by applicant]
US 20210401769A1
· Griesser et al.
· 2021
[cited by applicant]
US 20220096396A1
· Sebree et al.
· 2022
[cited by applicant]
US 20240122873A1
· Griesser et al.
· 2024
[cited by applicant]
AU 2018101357A4
· 2018
[cited by applicant]
CN 107126411A
· 2017
[cited by applicant]
GB 2549278A
· 2017
[cited by applicant]
WO 2006133941A2
· 2006
[cited by applicant]
WO WO2010127033A1
· 2010
[cited by applicant]
WO WO2016109624A1
· 2016
[cited by applicant]
WO 2016141056A1
· 2016
[cited by applicant]
WO WO2017068349A1
· 2017
[cited by applicant]
WO WO2017149387A1
· 2017
[cited by applicant]
WO WO2017151980A1
· 2017
[cited by applicant]
WO WO2017158539A1
· 2017
[cited by applicant]
WO WO2017178807A1
· 2017
[cited by applicant]
WO WO2017178810A1
· 2017
[cited by applicant]
WO WO2017182950A1
· 2017
[cited by applicant]
WO 2018011808A1
· 2018
[cited by applicant]
WO WO2018002637A1
· 2018
[cited by applicant]
WO WO2018109471A1
· 2018
[cited by applicant]
WO 2019034985A1
· 2019
[cited by applicant]
WO 2019089583A1
· 2019
[cited by applicant]
WO 2022017942A1
· 2022
[cited by applicant]
U.S. Appl. No. 16/737,326.
[cited by applicant]
U.S. Appl. No. 17/895,008.
[cited by applicant]
U.S. Appl. No. 17/941,739.
[cited by applicant]
U.S. Appl. No. 17/942,068.
[cited by applicant]
Busquets-Garcia, Arnau, et al., Targeting the endocannabinoid system in the treatment of fragile X syndrome, Nature Medicine (Mar. 2013).
[cited by applicant]
International Search Report and Written Opinion of corresponding PCT/IB2019/060735, mailed Mar. 3, 2020, 12 pages.
[cited by applicant]
Banks S, O'Neill C, Sebree T. Pharmacokinetic Evaluation of Subcutaneously Administered ZYN001 in Male Sprague-Dawley Rats. PAINWeek. Sep. 8-12, 2015.
[cited by applicant]
Bergmaschi et al., Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naiver Social Phobia Patients, Neuropsychopharmacology (2011) 36, 1219-1226.
[cited by applicant]
Blessing et al., Cannibidiol as a Potential Treatment for Anxiety Disorders, Neurotherapeutics, Oct. 2015, 12(4): 825-836.
[cited by applicant]
Bonn-Miller M, Banks SL, Sebree T. Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. Cannabis and Cannabinoid Research 2017;2:1, 5-7.
[cited by applicant]
Bonn-Miller M, Gutterman D. A Permeation-Enhanced Synthetic Cannabidiol (CBD) Transdermal Gel for the Treatment of PTSD. Military Health System Research Symposium. Orlando, FL. Aug. 15-18, 2016.
[cited by applicant]
Bonn-Miller M, Sebree T, O'Neill C, Messenheimer J. Neuropsychological Effects of ZYN002 (Synthetic Cannabidiol) Transdermal Gel in Healthy Subjects and Patients with Epilepsy: Phase 1, Randomized, Double-Blind, Placebo…
[cited by applicant]
Fusar-Poli, et al., “Modulation of Effective Connectivity During Emotional Processing by A9- tetrahydrocannabinol and Cannabidiol,” International Journal of Neuropsychopharmacology (2010) 13, 421-432.
[cited by applicant]
Gauvin D, O'Neill C, Patterson DR. Respiratory Evaluation of Subcutaneously Administered ZYN001 in Male Sprague-Dawley Rats. PAINWeek. Sep. 8-12, 2015.
[cited by applicant]
Jung KM, Sepers M, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012;3:1080.
[cited by applicant]
Kidd, et al., Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies, Pediatric Neurology, 88 (2018) 10-11.
[cited by applicant]
Lozano, et al., “Advances in the Understanding of Gabaeric Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder,” Curr Pharm Des Author manuscript, (2015); 21 (34): 4972-4…
[cited by applicant]
Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid.
[cited by applicant]
Novagant Corp. Announces Breakthrough in Cannabidiol (CBD) Transdermal Patch for Localized Delivery, Oct. 29, 2014.
[cited by applicant]
O'Brien T MD, FRACP; Berkovic, S, MD, FRACP; French, J, MD, et al. Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults. 2017 American Epilepsy Society Annual Meeting, Washington, DC. Dec. 1-5…
[cited by applicant]
Paudel KS, Hammell DC, et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Development and Industrial Pharmacy 2010;36(9):1088-1097.
[cited by applicant]
Qin M, Zeidler Z, et al. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.
[cited by applicant]
Salgado, et al., Autism Spectrum Disorder and Cannabidiol: Have We Seen This Movie Before?, Global Pediatric Health, vol. 5:1-5 (2018).
[cited by applicant]
Sativex Product Monograph, Buccal Spray, Mar. 30, 2012 (55 pages).
[cited by applicant]
Sebree T, O'Neill C, Messenheimer J, Gutterman D. Safety and Tolerability of ZYN002 (Synthetic Cannabidiol) Transdermal Permeation-Enhanced Gel in Healthy Subjects and Epilepsy Patients: Three Phase 1, Randomized, Doubl…
[cited by applicant]
Wei, et al., Enhancement of Anandamide-Mediated Endocannabinoid Signally Corrects Autism-Related Social Impairment, Cannabis and Cannabinoid Research, vol. 1.1 (2016).
[cited by applicant]
Wheeler, et al., “Anxiety, Attention Problems, Hyperactivity, and the Aberrant Behavior Checklist in Fragile X Syndrome,” American Journal of Medical Genetics, (2013) 141-155.
[cited by applicant]
Winton-Brown, et al., “Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMR1 Study,” Neuropsychopharmacology (2011) 36, 1340-1348.
[cited by applicant]
Hadland, S., et al., “Medical Marijuana: Review of the Science and Implications for Developmental Behavioral Pediatric Practice,” J Dev Behav Pediatr. 2015 ; 36(2): 115-123.
[cited by applicant]
Aran, A., et al., “Cannabidiol Based Medical Cannabis in Children with Autism—a Retrospective Feasibility Study (P3.318),” Neurology, 90:15 Supplement, (2018).
[cited by applicant]
Pavlovic, Zoran M., “Cannabinoids in Autism and Fragile X Syndrome: Value-Based Treatment Revolution Ahead?,” Global Journal of Intellectual & Developmental Disabilities, 3(1) 1-4 (Sep. 2017).
[cited by applicant]
Khalil, Rami Bou, “Would some cannabinoids ameliorate symptoms of autism?”, European Child & Adolescent Psychiatry, 21(4):237-238, XP035037636, ISSN: 1435-165X, DOI: 10.1007/S00787-012-0255-Z (2017).
[cited by applicant]
Anonymous: History of Changes for Study: NCT02956226, “Cannabinoids for Behavioral Problems in Children with ASD (CBA)”, XP055718101, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT02956226?V…
[cited by applicant]
Hammell, D.C., et al., “Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis”, Eur. J. Pain, vol. 20(6):936-948. doi:10.1002/ejp.818 (Jul. 2016).
[cited by applicant]
Heussler, Helen et al., “A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome”, Journal of Neurodevelopmental…
[cited by applicant]
Belmonte, Matthew K., et al., “Fragile X syndrome and autism at hte intersection of genetic and neural networks”, Nature Neuroscience, vol. 9(10):1221-1225 (2006).
[cited by applicant]
Hagerman, Randi, et al., “Fragile X Syndrome and Targeted Treatment Trials”, National Institutes of Health Public Access Manuscript, published as Results Probl Cell Differ., vol. 54:297-335. doi:10.1007/978-3-642-21649-…
[cited by applicant]
Kaufmann, Walter E., et al., “Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment”, HHS Public Access Manuscript, published as Pediatrics, vol. 139(Suppl 3):S194-S206. doi:10.154…
[cited by applicant]
Pisante, S., et al., “Cannabidiol: State of the Art and New Challenges for Therapeutic Applications”, Pharmacology and Therapeutics, vol. 175, pp. 133-150 (2017).
[cited by applicant]
Mechoulam, Raphael, et al., “Cannabidiol: An Overview of Some Pharmacological Aspects”, The Journal of Clinical Pharmacology, vol. 42, Issue 51, pp. 11S-19S (2002).
[cited by applicant]
Mechoulam, Raphael, et al., “Cannabidiol—Recent Advances”, Chemistry & Biodiversity; vol. 4, pp. 1678-1692 (2007).
[cited by applicant]
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures (Aug. 7, 2017).
[cited by applicant]
Hagerman, Randi J., et al., “Fragile X-Associated Neuropsychiatric Disorders (FXAND),” Frontiers in Psychiatry, vol. 9. Article 564, pp. 1-9 (2018).
[cited by applicant]
Crawford, Dana C., et al., “FMR1 and the Fragile X Syndrome: Human Genome Epidemiology Review,” Genet. Med., Author manuscript, HHS Public Access, vol. 3(5):359-371 (2001).
[cited by applicant]
Godler, David Eugeny, et al., “Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio,” Human Molecular Genetics, vol. 9(18):1618-1632 (2010).
[cited by applicant]
SDCAadmin, “The Difference Between Moderate to Severe Autism,” Sarah Dooley Center for Autism, pp. 1-6 (2019).
[cited by applicant]
Aran, Adi, et al., “Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study,” Journal of Autism and Developmental Disorders, vol…
[cited by applicant]
Hagerman, Randi J., et al., “High Functioning Fragile X Males: Demonstration of an Unmethylated Fully Expanded FMR-1 Mutation Associated with Protein Expression,” American Journal of Medical Genetics, vol. 51:298-308 (1…
[cited by applicant]
International Preliminary Report on Patentability for corresponding PCT/US2022/078449 dated Apr. 24, 2024, 9 pages.
[cited by applicant]
Ali, Shayma et al., “Efficacy of cannabinoids in paediatric epilepsy”, Developmental Medicine & Child Neurology, vol. 61:13-18 (2019).
[cited by applicant]
Kuchenbuch, Mathieu, et al., “Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy,” Epilepsia Open, vol. 5:496-500 (2020).
[cited by applicant]
SynGAP Research Fund, Webinar, CBD, Seizures & SynGAP: Parents Experience (2019).
[cited by applicant]
Vlaskamp, Danique R.M., et al., “SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy,” Neurology, vol. 92(2):e96-e107 (2019).
[cited by applicant]
“Lacking guidance from doctors, parents lead the charge in treating children with CBD,” Peninsula Press (2018).
[cited by applicant]
Salcedo-Arellano, Maria Jimena, et al., “Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments”, Neurotherapeutics, Springer International Publishing, Cham, vol…
[cited by applicant]
International Search Report and Written Opinion for corresponding PCT/US2022/078449 mailed Feb. 2, 2023, 13 pages.
[cited by applicant]
Hagerman, Paul J., Ph.D., M.D et al., Fragile X Syndrome: Diagnosis, Treatment, and Research, The Johns Hopkins University Press, pp. 210, 213, 471 and 472, 3rd Edition (2002).
[cited by applicant]
Liu, X. Shawn, et al., Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FRM1 Gene, Cell Press, vol. 172:979-992 (2018).
[cited by applicant]
Payan Gomez, Cesar, et al., “Variable Expressivity in Fragile X Syndrome: Towards the Identification of Molecular Characteristics That Modify the Phenotype”, The Application of Clinical Genetics, DovePress, vol. 14:305-…
[cited by applicant]
Clinical Leader: Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome, retrieved from the internet at URL:<https://www.clinicalleader.com/doc/zynerba-pharmaceut…
[cited by applicant]
Buckner, Julia D., et al., “Cannabis-related impairment and social anxiety: the roles of gender and cannabis use motives”, Addictive Behaviors, vol. 37(11):1294-1297 (2012).
[cited by applicant]
Fung, Wai Lun Alan, et al., “Elevated Prevalence of Generalized Anxiety Disorder in Adults 22q11.2 Deletion Syndrome”, American Journal of Psychiatry, vol. 167(8):998, XP009553437 (2010).
[cited by applicant]
Siegel, Steven, et al., Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS), ACNP 57th Annual Meeting: Poster Session III, Neuropsychopharmacology, vol. 43, Suppl. 1, pp. S399-S400, XP0931091…
[cited by applicant]
International Search Report and Written Opinion for corresponding PCT/IB2021/054543 dated Dec. 8, 2021, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability for corresponding PCT/IB2021/054543 dated Nov. 17, 2022, 7 pages.
[cited by applicant]
Maneeton, Narong, et al., “Risperidone for children and adolescents with autism spectrum disorder: a systematic review”, Neuropsychiatric Disease and Treatment, vol. 14:1811-1820 (2018).
[cited by applicant]
National Library of Medicine; Natonal Center for Biotechnology Information; PubChem; Compound Summary—Cannabidiol; 67 pages (2014).
[cited by applicant]
Heussler, H. et al., “Transdermal cannabidiol (CBD) Gel for the treatment of fragile X syndrome (FXS)”, 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL. 2018, Poster P5-092, …
[cited by applicant]
Cited By (2)